Back to top

Aprea Therapeutics announces new preclinical data, update on APR-1051

Aprea Therapeutics (APRE) announced new preclinical data and a clinical update on APR-1051, the Company’s next-generation oral WEE1 inhibitor, in h...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aprea Therapeutics, Inc. (APRE)